The Zacks Analyst Blog Highlights: Amazon, UnitedHealth, AbbVie, Simon Property And Autodesk

For Immediate Release

Chicago, IL –July 8, 2019 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Amazon (NASDAQ:AMZN) , UnitedHealth (NYSE:UNH) , AbbVie (NYSE:ABBV) , Simon Property Group (NYSE:SPG) and Autodesk (NASDAQ:ADSK) .

Here are highlights from Friday’s Analyst Blog:

Top Stock Reports for Amazon, UnitedHealth and AbbVie

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Amazon, UnitedHealth and AbbVie. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Amazon’s shares have outperformed the broader market in the past year (the stock is up +10.8% vs. the +7.4% increase for the S&P 500 as a whole). The Zacks analyst thinks Amazon continues to ride on its aggressive retail strategies, distribution strength and robust Prime program. Moreover, rapid adoption of Prime driven by customer benefits and strengthening grocery services is aiding its top line. Expanding content portfolio of Prime remains a tailwind.

Further, strengthening AWS services portfolio, rising number of availability zones and growing adoption are aiding Amazon’s dominance in the cloud space. Improving Alexa skills and growing advertisement business remain major positives.

However, intensifying competition in the cloud computing market from the likes of Microsoft (NASDAQ:MSFT) Azure and Google (NASDAQ:GOOGL) cloud is a significant headwind. Heavy investment in fulfillment centers remains a concern.

(You can read the full research report on Amazon here >>>).

Shares of UnitedHealth have lost -2.8% in the past year, underperforming the Zacks Medical Insurance industry, which has declined -1.4% over the same period. The Zacks analyst likes its strong operating performance, favorable business profile and disciplined enterprise risk management. It stands apart in the industry by virtue of healthcare services, technology and innovations offered by its unit, Optum.

Numerous acquisitions made by the company have broadened its business profile and provide benefits of diversification. Its solid balance sheet and consistent cash flow generation has enabled higher investment in business which will drive long term growth.

Capital management by dividend payment and share buyback is another positive. However, slowdown of growth in international operations and underperformance in Medicaid business are concerns. An increase in leverage and interest burden raises financial risk.

(You can read the full research report on UnitedHealth here >>>).

AbbVie’s shares have declined -21.3% year to date, underperforming the Zacks Large-Cap Pharmaceuticals industry's increase of +4.7%. The Zacks analyst thinks AbbVie’s key drug, Humira is performing well based on strong demand trends despite new competition. Imbruvica has multibillion dollar potential.

AbbVie has been successful in expanding approvals for its cancer drugs, Imbruvica and Venclexta. Moreover, AbbVie has an impressive late-stage pipeline comprising several products with multibillion-dollar potential expected to be launched in the near term. The acquisition of Allergan (NYSE:AGN), if successful, will add the former’s blockbuster Botox to AbbVie’s portfolio.

Sales erosion due to direct biosimilar competition to Humira in international markets will be a major headwind in 2019. Estimates have gone down ahead of Q2 earnings. However, AbbVie has a positive record of earnings surprises in the recent quarters.

(You can read the full research report on AbbVie here >>>).

Other noteworthy reports we are featuring today include Simon Property Group and Autodesk.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com

http://www.zacks.com

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.